2. D’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease.
3.
Eur Respir Rev 2012;21:328-337.
4.
3. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. DOI:10.1093/eurheartj/ehv317.
4. Denault A, Deschamps A, Tardif JC, et al. Pulmonary hypertension in cardiac surgery. Current Cardiology Reviews 2010;6:1-14.
6.
5. Beghetti M, Galie N, Bonnet D. Can “inoperable” congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis 2012;7:3-11.
7.
6. Lopes AA, Barst RJ, Haworth SG, et al. Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulm Circ 2014:4:330-341.
9. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oXide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Vasodilator capacity and cellular mechanisms. Circulation 2001;103:544-548.
12.
10. Theodoraki K, Rellia P, Thanopoulos A, et al. Inhaled iloprosl controls pulmonary hypertension after cardiopulmonary bypass. Can J Anesth 2002;49:963-967.
11. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pumonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007;93:350-354.
14.
12. Trachte AL, Lobato EB, Urdaneta F, et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005;79:194-197.